Compare MFIC & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIC | CMPX |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 955.1M |
| IPO Year | 2004 | N/A |
| Metric | MFIC | CMPX |
|---|---|---|
| Price | $11.38 | $5.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $12.63 | ★ $13.44 |
| AVG Volume (30 Days) | 833.1K | ★ 2.1M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | ★ 13.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $324,678,000.00 | N/A |
| Revenue This Year | $9.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.73 | ★ N/A |
| Revenue Growth | ★ 11.35 | N/A |
| 52 Week Low | $10.18 | $1.33 |
| 52 Week High | $14.74 | $5.86 |
| Indicator | MFIC | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 52.52 |
| Support Level | $11.04 | $4.79 |
| Resistance Level | $11.65 | $5.70 |
| Average True Range (ATR) | 0.22 | 0.33 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 44.44 | 51.38 |
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.